The executive director of the organization says gender inequality is one of the most important drivers of new infections, ...

The U.S Food and Drug Administration ( FDA) has confirmed the availability of lenacapavir, a two-yearly injectable HIV/ADS treatment as early as the summer 2025, a decision made by FDA after the ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

In a groundbreaking development for HIV prevention, the efficacy and safety of a six-monthly injection containing the antiretroviral drug lenacapavir have been confirmed through two pivotal studies.

GILD's recent upbeat data on lenacapavir underscore the investigational drug???s potential to prevent HIV in the targeted ...

New data from the PURPOSE 2 trial continue to show the efficacy of lenacapavir in HIV prevention in individuals who have sex ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

In this randomized controlled trial, among adolescent girls and young women, it was found that twice-yearly lenacapavir ...

Gilead Sciences, the maker of a twice-a-year anti-HIV injection, has approached South Africa’s medicine regulator to discuss ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

1 This randomised controlled trial found that twice yearly injection of the drug lenacapavir for pre-exposure prophylaxis (PrEP) was 100% effective at preventing HIV infection in cisgender women and ...